Person:
YILMAZTEPE ORAL, ARZU

Loading...
Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Organizational Unit

Job Title

Last Name

YILMAZTEPE ORAL

First Name

ARZU

Name

Search Results

Now showing 1 - 7 of 7
  • Publication
    Unfolded protein response is involved in trans-platinum (ii) complex-induced apoptosis in prostate cancer cells via ros accumulation
    (Bentham Science Publ Ltd, 2019-01-01) Karakaş, Didem; Cevatemre, Buse; Oral, Arzu Y.; YILMAZTEPE ORAL, ARZU; Yılmaz, Veysel T.; YILMAZ, VEYSEL TURAN; Ulukaya, Engin; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.; Bursa Uludağ Üniversitesi/Fen Edebiyat Fakültesi/Kimya Bölümü.; 0000-0002-3781-6834; 0000-0002-8962-9758; 0000-0002-2849-3332; AHD-2050-2022; KMA-2321-2024; A-5841-2017; L-7238-2018; L-6682-2018
    Background: Prostate cancer is one of the most common cancer types and it is the sixth leading cause of cancer-related death in men worldwide. Even though novel treatment modalities have been developed, it still a lifethreatening disease. Therefore novel compounds are needed to improve the overall survival.Methods: In our study, it was aimed to evaluate the anti-cancer activity of newly synthesized Platinum (II) [Pt(II)] complex on DU145, LNCaP and PC-3 prostate cancer cell lines. The cytotoxic activity of Pt(II) complex was tested by SRB and ATP cell viability assays. To detect the mode of cell death; fluorescent staining, flow cytometry and western blot analyses were performed.Results: The Pt(II) complex treatment resulted in a decrease in cell viability and increasing levels of apoptotic markers (pyknotic nuclei, annexin-V, caspase 3/7 activity) and a decrease in mitochondrial membrane potential in a dose dependent manner. Among cell types, tested PC-3 cells were found to be more sensitive to Pt(II) complex, demonstrating elevation of DNA damage in this cell line. In addition, Pt(II) complex induced Endoplasmic Reticulum (ER) stress by triggering ROS generation. More importantly, pre-treatment with NAC alleviated Pt(II) complex-mediated ER stress and cell death in PC-3.Conclusion: These findings suggest an upstream role of ROS production in Pt(II) complex-induced ER stressmediated apoptotic cell death. Considering the ROS-mediated apoptosis inducing the effect of Pt(II) complex, it warrants further evaluation as a novel metal-containing anticancer drug candidate.
  • Publication
    Serum endocan and indoleamine 2,3 dioxygenase levels and diagnostic value in acne rosacea
    (Wiley, 2019-07-01) Odabaşı, M. S.; Oral, Arzu Yılmaztepe; YILMAZTEPE ORAL, ARZU; Uludağ Üniversitesi/Fen-Edebiyat Fakültesi/Biyokimya Bölümü; 0000-0002-8962-9758; A-5841-2017
  • Publication
    Serum indoleamine 2,3-dioxygenase level and diagnostic value in patients with rosacea
    (Wolters Kluwer Medknow Publications, 2023-01-01) Odabaşı, Merve Sena; YAZİCİ, SERKAN; Özkaya, Güven; ÖZKAYA, GÜVEN; Başkan, Emel Bülbül; YILMAZTEPE ORAL, ARZU; BÜLBÜL BAŞKAN, EMEL; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.; 0000-0001-6407-0962; 0000-0003-0297-846X; JAX-2733-2023; A-4421-2016
    Background: Indoleamine 2,3-dioxygenase (IDO), an enzyme in the first step of tryptophan catabolism, plays a role in the pathogenesis of various malignancies and inflammatory diseases. Although its pathogenesis is unclear, vascular dysregulation and chronic inflammation are the most common culprits for rosacea. Objectives: The aim of this study is to evaluate the relationship between IDO and rosacea and whether there is a correlation with disease severity. Methods: Fifty-two patients with rosacea and 29 healthy volunteers were recruited. The patients were grouped according to severity stage, period, and subtype of the disease. Serum IDO levels were measured with enzyme-linked immunosorbent assay. Results: Serum IDO levels were significantly higher in the patients with rosacea compared to the healthy controls (P < 0.001) and were significantly higher in the patients in remission period and with papulopustular type rosacea compared to the controls (P = 0.002 and P = 0.001, respectively). The serum IDO levels of the female rosacea patients were higher than those of the healthy female controls (P < 0.001). When the diagnostic value of the parameter was investigated, it was observed that the serum IDO level has high sensitivity (83.3%) and specificity (76.1%), with a cutoff value of 47.1 ng/mL for female rosacea patients. Conclusion: IDO was found to increase in rosacea patients. With the high specificity and sensitivity observed, especially in female patients, IDO may be a supporting parameter in the diagnosis of rosacea.
  • Publication
    The evaluation to relationship between serum vascular endothelial growth factor (VEGF) level, metastases and other tumor markers in patients with lung cancer
    (Turkish Assoc Tuberculosis & Thorax, 2008-01-01) Sağlam, Dursun Ali; Ursavaş, Ahmet; Karadağ, Mehmet; Oral, Arzu Yılmaztepe; Coşkun, Funda; Gözü, R. Oktay; Sağlam, Dursun Ali; KARADAĞ, MEHMET; URSAVAŞ, AHMET; YILMAZTEPE ORAL, ARZU; COŞKUN, NECMİYE FUNDA; Gözü, R. Oktay; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyokimya Anabilim Dalı.; 0000-0002-9027-1132; 0000-0002-8962-9758; 0000-0003-3604-8826; DNS-0810-2022; AAI-3169-2021; AAG-8744-2021; A-5841-2017; AAD-1271-2019; JKV-0503-2023
    Vascular endothelial growth factor (VEGF) is a potent mediator of angiogenesis. Increased expression of VEGF may be associated with advanced stage and poor prognosis in patients with lung cancer. We investigated the relationship between serum VEGF level and lung cancer stage. We also studied the correlation between serum VEGF level and some other tumor markers. Forty newly diagnosed lung cancer (31 non-small cell, 9 small cell) patients and 25 age-matched controls were enrolled in this study. Serum VEGF levels of lung cancer group (345.16 +/- 159.36 pg/mL) were significantly higher than that of the control group (230.36 +/- 47.87 pg/mL) (p<0.001). The area under the ROC curve was 0.727 (p<0.05) for serum VEGF threshold of 249.8 pg/mL predictive sensitivity and specificity, for lung cancer were respectively 70.0% and 76.0%. There were no significant relationship between serum VEGF level and age, gender, histologic type, lung cancer stage, distant metastases and site of metastases. In addition, there were no correlation between serum VEGF level and other tumor markers (NSE, CYFRA 21-1, CEA, CA125, LDH)
  • Publication
    Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis
    (Baishideng Publishing Group Inc, 2007-02-14) Yılmaz, Yusuf; Dolar, Enver; Ulukaya, Engin; Akgöz, Semra; Keskin, Murat; Kıyıcı, Murat; Aker, Sibel; Yılmaztepe, Arzu; Gürel, Selim; Gülten, Macit; Nak, Selim Giray; Yılmaz, Yusuf; DOLAR, MAHMUT ENVER; Ulukaya, Engin; GÜREL, SELİM; NAK, SELİM GİRAY; Akgöz, Semra; Keskin, Murat; KIYICI, MURAT; Aker, Sibel; YILMAZTEPE ORAL, ARZU; GÜLTEN, MACİT; Uludağ Üniversitesi/Tıp Fakültesi/Dahiliye Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İstatistik Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0003-4518-5283; 0000-0003-4875-5472; 0000-0003-4526-4352; 0000-0002-3208-6211; 0000-0002-8962-9758; K-6651-2012; AAG-9177-2021; K-5792-2018; EKV-4953-2022; JZY-7001-2024; AAI-4213-2021; EJH-8721-2022; A-5841-2017; HLH-8209-2023; EYR-7166-2022; FQM-3662-2022
    AIM: To investigate whether serum levels of two soluble forms of extracellular cytokeratin 18 (M30-antigen and M65-antigen) may differentiate nonalcoholic steatohepatitis (NASH) from simple steatosis in patients with nonalcoholic fatty liver disease (NAFLD).METHODS: A total of 83 patients with suspected NAFLD and 49 healthy volunteers were investigated. Patients with suspected NAFLD were classified according to their liver histology into four groups: definitive NASH (n = 45), borderline NASH (n = 24), simple fatty liver (n = 9), and normal tissue (n = 5). Serum levels of caspase-3 generated cytokeratin-18 fragments (M30-antigen) and total cytokeratin-18 (M65-antigen) were determined by ELISA.RESULTS: Levels of M30-antigen and M65-antigen were significantly higher in patients with definitive NASH compared to the other groups. An abnormal value (> 121.60 IU/L) of M30-antigen yielded a 60.0% sensitivity and a 97.4% specificity for the diagnosis of NASH. Sensitivity and specificity of an abnormal M65-antigen level (> 243.82 IU/L) for the diagnosis of NASH were 68.9% and 81.6%, respectively. Among patients with NAFLD, M30-antigen and M65-antigen levels distinguished between advanced fibrosis and early-stage fibrosis with a sensitivity of 64.7% and 70.6%, and a specificity of 77.3% and 71.2%, respectively.CONCLUSION: Serum levels of M30-antigen and M65-antigen may be of clinical usefulness to identify patients with NASH. Further studies are mandatory to better assess the role of these apoptonecrotic biomarkers in NAFLD pathophysiology. (C) 2007 The WJG Press. All rights reserved.
  • Publication
    Can heat shock protein 32 be used for the early diagnosis of acute mesenteric ischemia?
    (Türk Cerrahi Derneği, 2016-03-01) Berhuni, Sait; Öztürk, Ersin; Oral, Arzu Yılmaztepe; Sarkut, Pınar; Kahveci, Nevzat; Yılmazlar, Tuncay; Özlük, Kasım; Yerci, Ömer; Berhuni, Sait; Öztürk, Ersin; YILMAZTEPE ORAL, ARZU; Sarkut, Pınar; KAHVECİ, NEVZAT; YILMAZLAR, AHMET TUNCAY; Özlük, Kasım; YERCİ, ÖMER; Uludağ Üniversitesi/Tıp Fakültesi/Genel Cerrahi Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Fizyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0002-8962-9758; 0000-0003-0841-8201; AAG-7070-2021; A-5841-2017; CEH-4566-2022; JGW-0566-2023; HKB-5363-2023; CKK-3621-2022; JJX-0104-2023; EIS-5114-2022
    Objective: Acute mesenteric ischemia is a challenging and fatal disease. The aim of this study was to detect the heat shock protein 32 (HSP32) response in intestinal tissue and systemic blood to intestinal ischemia and ischemia/reperfusion to define a tool for the early diagnosis of acute mesenteric ischemia.Material and Methods: Thirty female Wistar albino rats were equally divided into 3 groups. Group 1 rats underwent simple laparotomy and closure (control). In Group 2 rats, 1-hour intestinal ischemia followed by 5-hour reperfusion was performed, and Group 3 rats were subjected to 6-hour intestinal ischemia. The experiment was repeated with a 24-hour waiting period. At the end of the waiting period, blood was withdrawn from the tail veins of the rats and the rats were sacrificed via cardiac puncture. Re-laparotomy was subsequently performed and intestinal tissue and luminal samples were obtained for biochemical and pathological investigations. The HSP32 levels of intestinal tissues, luminal contents and blood levels were compared among the groups.Results: At the end of the 24-hour waiting period, the median tissue HSP32 levels were 0.43 (0-6.6) ng/mL for Group 1, 9.51 (2.5-49.9) ng/mL for Group 2 and 43.13 (6.3-121.3) ng/mL for Group 3 (p= 0.001). The median blood HSP32 levels were 0.11 (0.1-1.4) ng/mL for Group 1, 0.42 (0.1-0.7) ng/mL for Group 2, and 0.25 (0.1-1.2) ng/mL for Group 3 (p= 0.047). The HSP levels in the luminal contents were undetectable.Conclusion: Both ischemia and ischemia/reperfusion significantly raised intestinal tissue HSP32 levels in comparison with the control group. However, this change was not reflected in the circulating blood or luminal contents.
  • Publication
    Impact of preventive actions on rejection rates in the preanalytical period
    (Walter De Gruyter Gmbh, 2020-02-01) Odabaşı, Merve Sena; Dirican, Melahat; Oral, Arzu Yılmaztepe; YILMAZTEPE ORAL, ARZU; Özkaya, Guven; ÖZKAYA, GÜVEN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.; 0000-0003-3774-4241; 0000-0002-8962-9758; 0000-0003-0297-846X; AAG-6985-2021; A-5841-2017; A-4421-2016
    Background: It is responsibility of medical laboratories to determine and reject nonconforming samples as well as take preventive actions. In this study, we examined reasons and percentages of rejected samples. We also investigated impact of the preventive actions on decreasing the rejection rates.Materials and methods: Reasons for rejection were determined by Pareto analysis. Sigma analysis was used for each month to evaluate the ratios and compare with other studies. Some preventive actions were taken to reduce the rejection rates. Pearson's chi square test was used to evaluate effects of preventive actions. Significance level was determined as p <0.05.Results: Most of the rejected samples consisted of samples not received by the laboratory, haemolysed and insufficient samples. The percentages of samples not received by the laboratory and insufficient samples were reduced from 3.80% to 1.94% and 0.33% to 0.31% respectively, while haemolysed samples percentage was increased from 2.83% to 3.37% after the improvement actions. Also, sigma levels for samples not received by the laboratory and haemolysed samples were at the minimum while insufficient samples were at a reasonable level.Conclusion: Improvement actions achieved statistically significant decreases for samples not received by the laboratories for a long-term.